NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
40
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
stocks
ASX healthcare share remains cheap despite mixed earnings result
stocks
Wide moat ASX share beats earnings guidance
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,404.70 | 0.80 | -0.01% |
| CAC 40 | 8,661.47 | 53.47 | -0.61% |
| DAX 40 | 26,324.54 | 66.88 | -0.25% |
| Dow JONES (US) | 53,761.81 | 30.04 | -0.06% |
| FTSE 100 | 10,813.67 | 30.52 | -0.28% |
| HKSE | 25,440.17 | 212.65 | -0.83% |
| NASDAQ | 26,571.66 | 126.22 | 0.48% |
| Nikkei 225 | 67,524.06 | 553.84 | 0.83% |
| NZX 50 Index | 13,737.66 | 123.00 | -0.89% |
| S&P 500 | 7,743.66 | 15.46 | 0.20% |
| S&P/ASX 200 | 9,209.40 | 2.20 | -0.02% |
| SSE Composite Index | 3,946.68 | 12.58 | 0.32% |